Peer-influenced content. Sources you trust. No registration required. This is HCN.
The New England Journal of Medicine
This Phase 1-2 study presents compelling evidence for the efficacy of mezigdomide in combination with dexamethasone for patients with relapsed and refractory multiple myeloma. Explore the study to understand how this novel treatment could eventually fit into your therapeutic strategy.
Hematology/Oncology September 5th 2023
OBR Oncology
The FDA’s accelerated approval of elranatamab offers a new therapeutic pathway for adults with relapsed or refractory multiple myeloma. With promising response rates and an established safety profile, this treatment may provide a much-needed option for those struggling with relapsed myeloma.
Hematology/Oncology August 21st 2023
Roswell Park
The recent study by Roswell Park Comprehensive Cancer Center demonstrates that exercise may significantly impact the immune system in multiple myeloma patients. Explore the potential of this nonpharmaceutical approach to enhance immune function and provide a new avenue for controlling this blood cancer.
Hematology/Oncology August 14th 2023
The phase 3 study evaluating cilta-cel, a BCMA–directed CAR T-cell therapy, in patients with lenalidomide-refractory multiple myeloma indicates promising results in progression-free survival and overall response rates.
Hematology/Oncology August 1st 2023
Prova Education
Join this crucial journey to broaden your comprehension of CAR T-cell therapy, CRS and ICANS management, and learn how to utilize this knowledge for better patient outcomes in the battle against relapsed/refractory multiple myeloma.
Nursing July 3rd 2023
Oncology Learning Network
Cilta-cel CAR-T-cell therapy: A ray of hope for refractory multiple myeloma patients. A new study on ciltacabtagene autoleucel CAR-T-cell therapy (cilta-cel) shows promise for relapsed/refractory multiple myeloma (RRMM) patients. Published in Blood, the study led by Dr. Adam Cohen from the University of Pennsylvania, focuses on patients with previous exposure to noncellular anti-B-cell maturation antigen (BCMA) therapies. The team’s objective was achieving the primary endpoint of minimal residual disease (MRD) negativity, alongside multiple secondary endpoints. They tested on patients above 18 with RRMM, progressive disease within 12 months of their last treatment or six months of prior therapy, and measurable disease at baseline. They conducted a multicohort study, primarily focusing on cohort C which entailed cilta-cel treatment. A total of 20 patients met the eligibility criteria and received cilta-cel. Among them, 35% had BsAb as their latest anti-BCMA treatment, while 65% had ADC. With a median follow-up of 11.3 months, 7 patients achieved MRD negativity. The overall response rate stood at 60%, with 55% achieving very good partial response (VGPR) or better, and 30% achieving complete remission (CR) or better. However, all patients experienced treatment-emergent adverse events, majorly grade 3 to 4 cytopenias. Most of these cytopenia events recovered to […]
Hematology May 30th 2023